MXPA04002496A - Composicion farmaceutica para el tratamiento de enfermedades urinarias. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades urinarias.

Info

Publication number
MXPA04002496A
MXPA04002496A MXPA04002496A MXPA04002496A MXPA04002496A MX PA04002496 A MXPA04002496 A MX PA04002496A MX PA04002496 A MXPA04002496 A MX PA04002496A MX PA04002496 A MXPA04002496 A MX PA04002496A MX PA04002496 A MXPA04002496 A MX PA04002496A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutically acceptable
precursors
mammal
pharmaceutical compositions
Prior art date
Application number
MXPA04002496A
Other languages
English (en)
Inventor
P Arneric Stephen
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,556 external-priority patent/US20030060513A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MXPA04002496A publication Critical patent/MXPA04002496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion pertenece al campo de la urologia. La invencion proporciona una composicion farmaceutica novedosa, que comprende una combinacion farmaceuticamente efectiva de (i) un primer compuesto seleccionado del grupo que consiste de antagonistas receptores muscarinicos, inhibidores 5a-reductasa y antagonistas receptores a-adrenergicos y precursores y sales farmaceuticamente aceptables del mismo y (ii) un segundo compuesto seleccionado del grupo que consiste de agonistas y antagonistas del receptor 5-HT1a, y precursores y sales farmaceuticamente aceptables del mismo y opcionalmente un portador o diluyente farmaceuticamente aceptable del mismo. Tambien se proporciona un metodo para el tratamiento terapeutico de una enfermedad urinaria en un mamifero, incluyendo al hombre, que comprende administrar a dicho mamifero, incluyendo al hombre, en necesidad de dicho tratamiento, una cantidad terapeuticamente efectiva de una composicion de conformidad con la invencion.
MXPA04002496A 2001-09-27 2002-09-26 Composicion farmaceutica para el tratamiento de enfermedades urinarias. MXPA04002496A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/965,556 US20030060513A1 (en) 2001-09-27 2001-09-27 Pharmaceutical composition
SE0103858A SE0103858D0 (sv) 2001-09-27 2001-11-20 Pharmaceutical composition
PCT/SE2002/001748 WO2003026564A2 (en) 2001-09-27 2002-09-26 Pharmaceutical compositions for the treatment of urinary disorders

Publications (1)

Publication Number Publication Date
MXPA04002496A true MXPA04002496A (es) 2004-05-31

Family

ID=26655594

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002496A MXPA04002496A (es) 2001-09-27 2002-09-26 Composicion farmaceutica para el tratamiento de enfermedades urinarias.

Country Status (9)

Country Link
EP (1) EP1438035A2 (es)
JP (1) JP2005503424A (es)
KR (1) KR20040039436A (es)
CN (1) CN1558756A (es)
BR (1) BR0212824A (es)
CA (1) CA2461731A1 (es)
IL (1) IL160852A0 (es)
MX (1) MXPA04002496A (es)
WO (1) WO2003026564A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
FR2843303B1 (fr) * 2002-08-07 2006-01-21 R & D Pharma Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
WO2009151613A1 (en) * 2008-06-13 2009-12-17 Concert Pharmaceuticals, Inc. Oxybutynin derivatives
EP2363397A4 (en) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co NEW THERAPEUTIC AGENT USEFUL FOR SYMPTOM OF LOWER URINARY TRACT
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138094A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417135D0 (en) * 1994-08-23 1994-10-12 Medinnova S F Method
IT1282705B1 (it) * 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
AU731576B2 (en) * 1997-10-28 2001-04-05 Merck & Co., Inc. Prevention of precipitated acute urinary retention
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
IT1314192B1 (it) * 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati benzopiranici

Also Published As

Publication number Publication date
WO2003026564A3 (en) 2003-12-11
IL160852A0 (en) 2004-08-31
JP2005503424A (ja) 2005-02-03
EP1438035A2 (en) 2004-07-21
WO2003026564A9 (en) 2004-06-17
CN1558756A (zh) 2004-12-29
WO2003026564A2 (en) 2003-04-03
CA2461731A1 (en) 2003-04-03
BR0212824A (pt) 2004-10-13
KR20040039436A (ko) 2004-05-10

Similar Documents

Publication Publication Date Title
TW200642685A (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
MXPA05004381A (es) Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
RU2001133004A (ru) Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции
TW200621249A (en) Substituted amide beta secretase inhibitors
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
PT1230236E (pt) Composto com propriedades de libertacao de hormonas de crescimento
SE0102055D0 (sv) New Compounds
MXPA04002496A (es) Composicion farmaceutica para el tratamiento de enfermedades urinarias.
DE69533194D1 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
SE0103858D0 (sv) Pharmaceutical composition
AU2002364953A8 (en) Topoisomerase poison agents
EP1419129A4 (en) USE OF BRANCHED CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
RU2007143434A (ru) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
WO2005021040A3 (en) Compositions useful for treating gastrointestinal motility disorders
AU2002362008A1 (en) Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
WO2002040477A3 (en) Saframycins, analogues and uses thereof